Recipients of a Cochlear Nucleus system whose initial programming occurs on or after Augwill be eligible to exchange one of their current sound processors at no charge This next generation device is pending regulatory approval in the US and Canada, and there is no current timeline for approval or availability With this information becoming public knowledge, we wanted your patients to be confident they would have access to the new technology without delaying surgery. In support of this belief, any candidate who selects a Nucleus cochlear implant system and has an initial programming session that occurs on or after Augwill be eligible to exchange one of their sound processors for the next generation device when it becomes available.Īugis the selected eligibility date as it correlates with our global investor relations announcement of this new device. We firmly believe earlier access to sound is extremely important and want to ensure your patients are not waiting to move forward with cochlear implantation. I thought this would be helpful to some people here considering how high the anticipation of this new device has been.Ĭochlear Americas is pleased to announce the upcoming introduction of our next generation Nucleus® behind-the-ear sound processor. Despite our excitement and anticipation, we are unable to share its key features and benefits at this time, however we can tell you that this sound processor is a direct result of our commitment to technological innovation and market leading investment in research and development. In no event shall be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on, or relating to the use of, or inability to use, GuruFocus.My son's audiologist forwarded me an email she got from Cochlear this morning. Gurus may be added or dropped from the GuruFocus site at any time. The individuals or entities selected as 'gurus' may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. Under no circumstances does any information posted on represent a recommendation to buy or sell a security. This investment adviser does not provide advice to individual investors. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. All Rights Reserved.ĭisclaimers: is not operated by a broker or a dealer. Stock List Guru List Insider List Insider Trade Economic Indicators Industry Data DCF Calculator Discussion Board Plans Excel Add-In Google Sheets Add-on.Home About Jobs Site Map Term of Use Privacy Policy Mobile App Referral Program Affiliate Program FAQ Contact Us 中文 All-In-One Screener.Payments to Suppliers for Goods and Services.Other Cash Receipts from Operating Activities.Other Cash Payments from Operating Activities.Cash Received from Insurance Activities.

Cash Receipts from Securities Related Activities.

Cash Receipts from Operating Activities.

Cash Receipts from Fees and Commissions.

Cash Receipts from Deposits by Banks and Customers.

Cash Payments for Deposits by Banks and Customers.

Cash from Discontinued Operating Activities.

Cash From Discontinued Investing Activities.

Short-Term Debt & Capital Lease Obligation.

Other Liabilities for Insurance Companies.

Long-Term Debt & Capital Lease Obligation.

Inventories, Raw Materials & Components.

Cash, Cash Equivalents, Marketable Securities.

Accumulated other comprehensive income (loss).

Accounts Payable & Accrued Expense for Financial Companies.Depreciation, Depletion and Amortization.Margin of Safety % (DCF Dividends Based).Margin of Safety % (DCF Earnings Based).Float Percentage Of Total Shares Outstanding.

Cochlear americas kanso 2